Long-term blood pressure patterns in midlife and dementia in later life: Findings from the Framingham Heart Study
- PMID: 37394941
- PMCID: PMC10597747
- DOI: 10.1002/alz.13356
Long-term blood pressure patterns in midlife and dementia in later life: Findings from the Framingham Heart Study
Abstract
Introduction: Long-term blood pressure (BP) measures, such as visit-to-visit BP variability (BPV) and cumulative BP, are strong indicators of cardiovascular risks. This study modeled up to 20 years of BP patterns representative of midlife by using BPV and cumulative BP, then examined their associations with development of dementia in later life.
Methods: For 3201 individuals from the Framingham Heart Study, multivariate logistic regression analyses were performed to examine the association between long-term BP patterns during midlife and the development of dementia (ages ≥ 65).
Results: After adjusting for covariates, every quartile increase in midlife cumulative BP was associated with a sequential increase in the risk of developing dementia (e.g., highest quartile of cumulative systolic blood pressure had approximately 2.5-fold increased risk of all-cause dementia). BPV was not significantly associated with dementia.
Discussion: Findings suggest that cumulative BP over the course of midlife predicts risk of dementia in later life. HIGHLIGHTS Long-term blood pressure (BP) patterns are strong indicators of vascular risks. Cumulative BP and BP variability (BPV) were used to reflect BP patterns across midlife. High cumulative BP in midlife is associated with increased dementia risk. Visit-to-visit BPV was not associated with the onset of dementia.
Keywords: blood pressure; dementia; midlife; prevention.
© 2023 the Alzheimer's Association.
Conflict of interest statement
Conflict of Interest
Dr. Thomas is co-inventor and patent holder of the ECG-derived sleep spectrogram, which may be used to phenotype sleep quality and central/complex sleep apnea. The technology is licensed by Beth Israel Deaconess Medical Center to MyCardio, LLC. He is also co-inventor and patent holder of the Positive Airway Pressure Gas Modulator, being developed for treatment of central/complex sleep apnea. He has consulted for Jazz Pharmaceuticals and consults for Guidepoint Global and GLG Councils. He is co-inventor of a licensed auto-CPAP software to DeVilbiss-Drive. Dr. Au is a scientific advisor for Signant Health & Biogen and a consultant for Biogen and the Davos Alzheimer’s Collaborative. None of these are conflicts relative to this project. No other authors have any conflicts of interest to disclose.
Figures
References
-
- As Association. Alzheimer’s Disease Facts and Figures. 2019.
-
- Organization WH. Dementia. 2022.
-
- Livingston G, Sommerlad A, Orgeta V, Costafreda SG, Huntley J, Ames D, et al. Dementia prevention, intervention, and care. Lancet. 2017;390:2673–734. - PubMed
Publication types
MeSH terms
Grants and funding
- R01 NS017950/NS/NINDS NIH HHS/United States
- R01 AG054076/AG/NIA NIH HHS/United States
- R01 AG016495/AG/NIA NIH HHS/United States
- R01 AG049810/AG/NIA NIH HHS/United States
- RF1 AG062109/AG/NIA NIH HHS/United States
- ALZ/Alzheimer's Association/United States
- R01 AG008122/AG/NIA NIH HHS/United States
- AG016495/AG/NIA NIH HHS/United States
- AG008122/AG/NIA NIH HHS/United States
- P30 AG066546/AG/NIA NIH HHS/United States
- R01-NS017950/NS/NINDS NIH HHS/United States
- AG049810/AG/NIA NIH HHS/United States
- U19 AG068753/AG/NIA NIH HHS/United States
- N01 HC025195/HL/NHLBI NIH HHS/United States
- AG068753/AG/NIA NIH HHS/United States
- R56 AG062109/AG/NIA NIH HHS/United States
- AG062109/AG/NIA NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical
